IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$38.93 USD
-0.48 (-1.22%)
Updated Jun 13, 2024 04:00 PM ET
After-Market: $38.95 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
IDEAYA Biosciences, Inc. [IDYA]
Reports for Purchase
Showing records 101 - 120 ( 169 total )
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Broad Progress Across Pipeline; Investor Day Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
4Q20 - Momentum Builds Ahead of Two Key Readouts During 2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
4Q20 Results; First Patient Expected to be Dosed With IDE397 This Month
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Investor Meeting Takeaways - Focus on MAT2Ai IDE397 Program
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Presentations Announced for 2021 Annual Meeting of AACR
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Please Join Our Virtual 33rd Annual ROTH Conference on March 15 - 17th
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Ideaya to Host its Inaugural Synthetic Lethality Investor Day- April 20th
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Industry Veteran Susan Kelley, MD Joins Ideaya''s Board of Directors
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
FDA Clears IND to Launch Phase 1 Trial to Evaluate IDE397
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Maurer to Help Accelerate Development of Phase 1-Ready SL Program IDE397
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MAT2A Inhibitor IND Submission; Preclinical Data Points toLarge Opportunity
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R